Clinical Trial: An Integrated Genomic Approach to Assess Genetic Risk and Drug Sensitivity

U.S., April 30 -- ClinicalTrials.gov registry received information related to the study (NCT07555639) titled 'An Integrated Genomic Approach to Assess Genetic Risk and Drug Sensitivity' on Feb. 23.

Brief Summary: National multicenter prospective study, involving the enrollment of approximately 1,500 patients with ovarian cancer, 1,500 patients with breast cancer, and 1,000 patients with colorectal cancer.

Study Start Date: Nov. 21, 2019

Study Type: INTERVENTIONAL

Condition: Colon Cancer Breast Cancer Ovarian Cancer Genetic Risk Factors

Intervention: GENETIC: Genomic profile

This national multicenter prospective study will use the ACC Gersom NGS gene panel (172 cancer risk genes, 295 tumor-altered genes, 196 pharmacogenomic variants)...